PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING
Described herein are prostate specific membrane antigen (PSMA) binding conjugates that are useful for delivering therapeutic, diagnostic and imaging agents. Also described herein are pharmaceutical compositions containing them and methods of using the conjugates and compositions. Also described are processes for manufacture of the conjugates and the compositions containing them.
1 . A conjugate comprising a ligand of PSMA (B), a linker (L), and a drug (D), wherein the ligand includes one or more of a carbon-sulfur double bond, a phosphorus-sulfur double bond, a phosphorus-sulfur single bond, a thioester, or a combination thereof, and where the linker is covalently bound to the drug and the linker is covalently bound to the ligand, and where the linker comprises a chain of at least seven atoms.
2 . The conjugate of claim 1 wherein B is a compound of the formula
wherein X is RYP(S)(OH)CH 2 —; RYP(S)(OH)N(R 1 )—; RP(S)(OH)CH 2 —; RP(S)(OH)N(R 1 )—; RP(S)(OH)O—; RYC(S)N(R 1 )—; RN(OH)C(S)Y; RC(S)NHY; RYP(S)(SH)CH 2 —; RYP(S)(SH)N(R 1 )—; RP(S)(SH)CH 2 —; RP(S)(SH)N(R 1 )—; RP(S)(SH)S—; RN(SH)C(S)Y— or RC(S)N(OH)Y; or RS(O)Y, RSO 2 Y, RS(O)(NH)Y, and RS-alkyl, wherein Y is independently selected in each instance from-CR 1 R 2 —, —NR 3 —, —S—, and —O—, wherein R is hydrogen, alkyl, aryl, or arylalkyl, each of which may be optionally substituted; and q is 0 to 5; and
where R 1 , R 2 , and R 3 are each independently selected from hydrogen, C 1 -C 9 straight or branched chain alkyl, C 2 -C 9 straight or branched chain alkenyl, C 3 -C 8 cycloalkyl, C 5 -C 7 cycloalkenyl, and aryl.
3 . The conjugate of claim 2 wherein B is a compound of the formula
wherein X is RYP(S)(OH)CH 2 —; RYP(S)(OH)N(R 1 )—; RP(S)(OH)CH 2 —; RP(S)(OH)N(R 1 )—; RYC(S)N(R 1 )—; RYP(S)(SH)CH 2 —; RYP(S)(SH)N(R 1 )—, RP(S)(SH)CH 2 —; or RP(S)(SH)N(R 1 )—; wherein Y is independently selected in each instance from-CR 1 R 2 —, —NR 3 —, —S—, and —O—; wherein R is hydrogen, alkyl, aryl, or arylalkyl, each of which may be optionally substituted; and q is 0 to 5.
4 . The conjugate of claim 2 wherein q is 1.
5 . The conjugate of claim 2 wherein Y is independently selected in each instance from —CR 1 R 2 —, and —NR 3 —.
6 . The conjugate of claim 1 wherein the linker comprises a chain of at least 14 atoms.
7 - 13 . (canceled)
14 . The conjugate of claim 1 wherein the linker comprises a peptide.
15 . The conjugate of claim 1 wherein the linker comprises one or more phenylalanine residues, each of which is independently optionally substituted.
16 . (canceled)
17 . The conjugate of claim 1 wherein the linker comprises phenylalanyl-phenylalanyl, each of which is independently optionally substituted.
18 . The conjugate of claim 1 wherein the linker comprises a releasable linker.
19 - 22 . (canceled)
23 . The conjugate of claim 1 wherein the linker is non-releasable.
24 . (canceled)
25 . The conjugate of claim 1 wherein the ligand is a compound selected from the group consisting of
26 - 27 . (canceled)
28 . The conjugate of claim 1 wherein the ligand is a compound of the formula
wherein Q is a an amino dicarboxylic acid, such as aspartic acid, glutamic acid, or an analog thereof, n and m are each selected from an integer between 1 and about 6, and (*) represents the point of attachment for the linker L.
29 . The conjugate of claim 1 wherein the drug is selected from the group consisting of vinca alkaloids, taxanes, tubulysins, mitomycins, and camptothecins.
30 . The conjugate of claim 1 wherein the drug is an imaging agent selected from the group consisting of Oregon Greens, AlexaFluors, fluoresceins, BODIPY fluorescent agents, rhodamines, and DyLight fluorescent agents.
31 . The conjugate of claim 1 wherein the drug is a compound of the formula
wherein R is independently selected in each instance H, alkyl, heteroalkyl, cycloalkyl, heterocyclyl, alkenyl, alkynyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl, and the like, each of which is optionally substituted, where one R includes a heteroatom, such as nitro, oxygen, or sulfur, and is the point of attachment of linker L.
32 . The conjugate of claim 1 wherein the drug is a PET imaging agent.
33 . A pharmaceutical composition comprising a therapeutically effective amount of the conjugate of claim 1 , and a component selected from the group consisting of carriers, diluents, and excipients, and combinations thereof.
34 . A method for treating a disease involving a pathogenic cell population expressing PSMA, the method comprising the step of administering to a patient in need of relief from the disease a therapeutically effective amount of the conjugate of claim 1 , optionally with a component selected from the group consisting of carriers, diluents, and excipients, and combinations thereof.
35 . The conjugate of claim 3 wherein q is 1 and Y is independently selected in each instance from —CR 1 R 2 —, and —NR 3 —.